Application progress of non-vitamin K antagonist oral anticoagulants in hypertrophic cardiomyopathy with atrial fibrillation
10.3760/cma.j.cn431274-20230103-00005
- VernacularTitle:非维生素K拮抗口服抗凝药在肥厚型心肌病合并心房颤动中的应用进展
- Author:
Shaoshuai LIU
1
;
Siqi LYU
Author Information
1. 山东大学齐鲁医院（青岛）心内科，青岛 266035
- Keywords:
Cardiomyopathy, hypertrophic;
Atrial fibrillation;
Non-vitamin K antagonist oral anticoagulants
- From:
Journal of Chinese Physician
2023;25(11):1750-1754
- CountryChina
- Language:Chinese
-
Abstract:
Atrial fibrillation (AF) is the most common supraventricular arrhythmia in patients with hypertrophic cardiomyopathy. Patients with hypertrophic cardiomyopathy and atrial fibrillation have a significantly increased risk of thromboembolism. Currently, guidelines recommend lifelong anticoagulant therapy for all such patients. The data on the use of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation are limited, and their efficacy and safety are not well established. This article provides a review of the current evidence on this issue.
